Rein Therapeutics Inc Cash Flow Conversion Efficiency
Rein Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has a cash flow conversion efficiency ratio of -0.847x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.64 Million) by net assets ($10.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rein Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Rein Therapeutics Inc from 2015 to 2025. This chart illustrates how Rein Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RNTX stock price and chart for real-time trading data and today's change.
Rein Therapeutics Inc Cash Flow Conversion Ratio Explained
Rein Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rein Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rein Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Rein Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dhunseri Investments Limited
NSE:DHUNINV
|
-0.010x |
|
Konya Kagit Sanayi ve Ticaret AS
IS:KONKA
|
-0.023x |
|
Asia Hotel Public Company Limited
BK:ASIA
|
0.014x |
|
Dutaland Bhd
KLSE:3948
|
-0.019x |
|
Envoy Medical Inc.
NASDAQ:COCH
|
-1.652x |
|
City Service SE
WAR:CTS
|
0.058x |
|
Decibel Cannabis Company Inc
V:DB
|
0.028x |
|
Autopistas del Sol
BA:AUSO
|
0.005x |
Annual Cash Flow Conversion Efficiency for Rein Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Rein Therapeutics Inc from 2015 to 2025. Review RNTX financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.92 Million | $-19.36 Million | -1.144x | -179.24% |
| 2024-12-31 | $54.39 Million | $-22.29 Million | -0.410x | +85.75% |
| 2023-12-31 | $6.89 Million | $-19.81 Million | -2.876x | -115.41% |
| 2022-12-31 | $18.62 Million | $-24.86 Million | -1.335x | -146.78% |
| 2021-12-31 | $43.90 Million | $-23.75 Million | -0.541x | +67.86% |
| 2020-12-31 | $12.16 Million | $-20.48 Million | -1.684x | -2.06% |
| 2019-12-31 | $16.05 Million | $-26.47 Million | -1.650x | -15.78% |
| 2018-12-31 | $19.60 Million | $-27.93 Million | -1.425x | -231.70% |
| 2017-12-31 | $47.80 Million | $-20.53 Million | -0.430x | -419.87% |
| 2016-12-31 | $-111.81 Million | $-15.01 Million | 0.134x | +8.16% |
| 2015-12-31 | $-94.32 Million | $-11.71 Million | 0.124x | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more